Sino-American Pharmaceutical Professionals Association-New England (sapa-ne)
Download 122.5 Kb.
|
- Navigate this page:
- Design and Synthesis of VLA-/VCAM
- Biography
- Princeton, NJ 08543-5350
- Menlo Park, CA 94043
AbstractThe Pharmaceutical industry has been a major success story over the last century. In many ways our industry began with an understanding of the chemistry and biology of natural products, and evolved via synthetic chemistry towards the rational design of target specific molecules. How will the recent excitement around genomics, the explosion of information, increased data processing capacity and speed, and the continued need for novel medicines shape the pharmaceutical business of the future? Whilst predicting the future is probably futile, being prepared for changes in the way medicines are researched developed and marketed will be a pre-requisite for the successful companies of the future. Today's research and development productivity cannot hope to fuel the expected growth of our biggest companies. Small companies may lack the scale and critical mass to be successful. What will be the relationship between biotechnology and traditional pharmaceutical businesses? I personally believe that small molecules, which can be administered orally, will remain at the core of the prescription medicine market. Therefore biologically relevant chemistry must remain at the core of our discovery efforts. How do we make that chemistry more effective and more efficient? This is the challenge for companies like ArQule and many others. We are beginning to address this challenge in many innovative ways and I believe there is indeed reason for believing that our industry will continue to thrive in the next century- but only if we are bold and innovative. Biography Stephen Hill, B.M.B. Ch., M.A., F.R.C.S. joined the Company as President and CEO on April 1, 1999. Dr. Hill served as the Head of Global Drug Development at F. Hoffmann-La Roche Ltd. since 1997. He joined Roche in 1989 as Medical Adviser to Roche Products in the United Kingdom. He held several senior positions there, including that of Medical Director, with responsibility for clinical trials of compounds across a broad range of therapeutic areas, including those of CNS, HIV, cardiovascular, metabolic, and oncology products. Subsequently, he served as Head of International Drug Regulatory Affairs at Roche headquarters in Basel, Switzerland, where he led the regulatory submissions for seven major new chemical entities globally. He also was a member of Roche's Portfolio Management, Research, Development and Pharmaceutical Division Executive Boards. Prior to Roche, Dr. Hill served for seven years with the National Health Service in the United Kingdom, in General and Orthopedic Surgery. Dr. Hill is a Fellow of the Royal College of Surgeons of England, and holds his scientific and medical degrees from St. Catherine's College at Oxford University. Design and Synthesis of VLA-/VCAMAntagonists
AbstractThe adhesion molecule, VLA-4, plays a key role in the initiation and maintenance of the inflammatory process. Its interaction with its native receptor VCAM-1, an endothelial cell surface protein, leads to inflammatory cell recruitment. The disruption of the VLA-4/VCAM interaction represents a new therapeutic approach to inflammatory diseases such as asthma, atherosclerosis, multiple sclerosis, and rheumatoid arthritis. We have previously identified small molecules based on tosyl-proline-phenylalanine which inhibit the interaction between VLA-4 and its counter-receptor, VCAM-1. The genesis of these compounds will be discussed, as will their evolution to compounds exhibiting potent, and selective VLA-4 antagonism. BiographyDonna M. Huryn is Director of in the Department of Chemical Sciences at Wyeth-Ayerst Research. Prior to joining Wyeth-Ayerst, she held scientific positons at Hoffmann-La Roche. She received her undergraduate degree at Cornell University, and Ph.D. from the University of Pennsylvania working with Professor Amos B. Smith. Dr. Huryn’s current research includes the design and synthesis of therapeutics in the CNS area, as well as Inflammation, Cancer and Anti-Infective areas.
AbstractGenomics had lead to the identification of ~ 40,000 human genes, and proteomics will identify many more proteins from polymorphisms, transcript splicing and post-translational modifications. It is unclear precisely how many proteins will be drug targets for therapeutic intervention, but it is clear that our industry will face a growing number of targets with increasing complexity in the next ten years. Lead Identification and Optimization of drug-like small molecules at these targets are critically necessary steps in successful models of drug discovery. Although encoding and solid phase chemical synthesis technologies, as well as uHTS technologies, have made it possible to create and efficiently screen large chemical libraries of several million distinct compounds, it has been hypothesized that small collections of representative molecules are sufficient for Lead Identification. I will show data that indicates that it is often necessary to screen large collections of drug-like molecules, and that these molecules are capable of advancement to the clinic. Biography Maria Webb is Vice President of Drug Discovery Biology at Pharmacopeia in Princeton NJ where the focus is lead identification and optimization using Pharmacopeia’s platform technologies of combinatorial chemistry and high-throughput screening technologies. She received her Ph.D. in 1983 in Physiology from the Pennsylvania State University where she worked on steroid receptor physiology. From 1983 to 1985 she was an NIH fellow in Dr. Gerald Litwack’s lab at Temple University Medical School where she worked on steroid receptor biochemistry. In 1985, she moved to Hershey Medical Center of The Pennsylvania State University where she was a Research Assistant Professor working in steroid receptor regulation of transcription. In 1989, she moved to Bristol-Myers Squibb where she worked on numerous programs as part of the Cardiovascular Division including GPCR drug discovery programs targeted at thromboxane, angiotensin II and endothelin receptors before coming to Pharmacopeia in 1996. Modeling Biochemistry’s Versatile Processes: Cytochrome P450 Models for Drug Discovery and Development Ken Korzekwa, Ph.D.,Vice President of Research Camitro Corporation 4040 Campbell Avenue
Fax: (650) 327-4639 Email: kkorzekwa@camitro.com
Directory: conference conference -> Tilte : a critical examination of the police relations with bbc conference -> Eavesdropping on a virtuous circle Richard Whately and the Oriel Noetics. Elena Pasquini Douglas uwa business School conference -> Simulation and Prediction of Storm Surges, Waves, and Morphological Changes due to Tropical Cyclones by Using a pc-based Integrated Coastal Process Model conference -> Panel 0511 Disability and Difference I: Post-War Journeys through Disability conference -> Do remittances have a flip side? A general equilibrium analysis of remittances, labor supply responses and policy options for Jamaica* Maurizio Bussolo and Denis Medvedev conference -> Conference approval process made easy for acm in cooperation conferences conference -> Proceedings of gt2009 asme turbo Expo 2009: Power for Land, Sea and Air Orlando, Florida, USA gt2009-59981 dynamics of premixed h2/CH4 flames under near blowoff conditions conference -> South Korea’s Economic Future: Industrial Policy, or Economic Democracy? conference -> Asset rotator Cuff Rehabilitation Course Faculty Dr. Spero Karas conference -> Acm word Template for sig site Download 122.5 Kb. Share with your friends:
|